About: Secukinumab

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Secukinumab Goto Sponge NotDistinct Permalink

An Entity of Type : yago:Medicine103740161, within Data Space : wasabi.inria.fr associated with source document(s)

Secukinumab, sold under the brand name Cosentyx, is a human IgG1κ monoclonal antibody used for the treatment of psoriasis, ankylosing spondylitis, and psoriatic arthritis. It binds to the protein interleukin (IL)-17A and is marketed by Novartis.

Attributes	Values
type	Thing entity matter yago:CausalAgent100007347 yago:PhysicalEntity100001930 drug chemical substance chemical substance drug Chemical object Il- dbo:MonoclonalAntibody yago:Agent114778436 yago:Drug103247620 yago:Substance100020090 yago:Immunosuppressant103562958 yago:WikicatImmunosuppressants yago:Matter100020827 yago:Medicine103740161
label	Secukinumab Secukinumab Secukinumab Secuquinumab Секукинумаб セクキヌマブ
comment	Le secukinumab (appelé également AIN457) est un anticorps monoclonal dirigé contre l'interleukine 17A et utilisé comme médicament dans certaines affections rhumatologiques et dermatologiques. Secucinumab, com o nome comercial Cosentyx, é um anticorpo monoclonal humano produzido pela Novartis para o tratamento da psoríase. Este fármaco foi também aprovado para o tratamento da artrite psoriática e da espondilite anquilosante. O secucinumab atua por inibição seletiva da interleucina 17-A (IL-17A), uma citocina pró-inflamatória. Como consequência, o tratamento com secuquinumab reduz o eritema, o endurecimento e a descamação presentes na psoríase em placas. Secukinumab, sold under the brand name Cosentyx, is a human IgG1κ monoclonal antibody used for the treatment of psoriasis, ankylosing spondylitis, and psoriatic arthritis. It binds to the protein interleukin (IL)-17A and is marketed by Novartis. Секукинумаб — лекарственный препарат, моноклональное антитело. Одобрен для применения: США (2015). セクキヌマブ（Secukinumab、開発コードAIN457）は、非感染性慢性ぶどう膜炎、関節リウマチ、乾癬、強直性脊椎炎への治療効果を期待されている医薬品であり、サイトカインの一つインターロイキン-17Aに対するヒトモノクローナル抗体である。商品名コセンティクス(Cosentyx)。 Secukinumab (Handelsname Cosentyx) ist ein Arzneistoff aus der Gruppe der krankheitsmodifizierenden Antirheumatika (DMARDs). Es wird als Basistherapie zur Behandlung verschiedener Autoimmunerkrankungen eingesetzt, um sowohl die Symptome zu lindern als auch den Krankheitsverlauf zu verlangsamen. Hierzu gehören die Schuppenflechte (Plaque-Psoriasis und Psoriasis-Arthritis), die axiale Spondyloarthritis und die juvenile idiopathische Arthritis. Zur Behandlung mancher dieser Erkrankungen kann Secukinumab mit Methotrexat kombiniert werden. Secukinumab wird mittels Injektion in die Unterhaut (subkutan) verabreicht. Es ist ein monoklonaler Antikörper, der den Botenstoff Interleukin-17A (IL-17A) neutralisiert und dadurch bestimmte Entzündungs-, Immun- und Autoimmunreaktionen im Körper vermindert.
sameAs	secukinumab secukinumab secukinumab secukinumab secukinumab secukinumab secukinumab secukinumab secukinumab secukinumab secukinumab secukinumab secukinumab
topic	Psoriatic arthritis Ankylosing spondylitis dbr:ATC_code_L04 dbr:ATC_code_L04AC10 dbr:ATCvet_code_QL04AC10 Interleukin 17 Novartis monoclonal antibody therapy Psoriasis IL17A dbr:Interleukin-17_receptor Disease-modifying antirheumatic drug dbr:Bimekizumab dbr:Cosentyx dbr:List_of_therapeutic_monoclonal_antibodies wikipedia-en:Secukinumab dbr:List_of_drugs:_Se–Sh dbr:Secukinumab#this antiarthritic dbr:Injector_pen
depiction
described by	https://covidontheweb.inria.fr:4443/about/id/entity/http/dbpedia.org/resource/Endocytosis https://covidontheweb.inria.fr:4443/about/id/entity/http/dbpedia.org/resource/Inflammatory_bowel_disease https://covidontheweb.inria.fr:4443/about/id/entity/http/dbpedia.org/class/yago/Agent114778436 https://covidontheweb.inria.fr:4443/about/id/entity/http/dbpedia.org/resource/Cytokine https://covidontheweb.inria.fr:4443/about/id/entity/http/dbpedia.org/resource/Interleukin_17 https://covidontheweb.inria.fr:4443/about/id/entity/http/dbpedia.org/resource/Monoclonal_antibody https://covidontheweb.inria.fr:4443/about/id/entity/http/dbpedia.org/resource/Category:Monoclonal_antibodies https://covidontheweb.inria.fr:4443/about/id/entity/http/dbpedia.org/class/yago/Drug103247620 https://covidontheweb.inria.fr:4443/about/id/entity/http/dbpedia.org/resource/Template:Fdacite https://covidontheweb.inria.fr:4443/about/id/entity/http/dbpedia.org/resource/Category:Immunosuppressants
dbp:drugbank	DB09029
dbp:kegg	D09967
dbp:legalStatus	Rx-only
dbp:legalUk	POM
dbp:medlineplus	a615011
dbp:tradename	Cosentyx
subject	dbc:Novartis_brands Monoclonal antibodies Immunosuppressants Novartis dbc:Disease-modifying_antirheumatic_drugs
dbo:wikiPageID	33024133(xsd:integer)
Wikipage revision ID	1124043725(xsd:integer)
dbo:wikiPageWikiLink	Psoriatic arthritis cytokine Immunosuppressive drug inflammatory bowel diseases monoclonal antibody endocytosis Ankylosing spondylitis dbc:Novartis_brands Interleukin 17 Novartis European Medicines Agency Psoriasis

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software